CAI insider trading
NasdaqGS HealthcareCaris Life Sciences, Inc.: insider trade history from SEC Form 4 filings.
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Company website: www.carislifesciences.com
CAI insider activity at a glance
FilingIQ tracks 235 insider transactions for CAI in filings since Oct 26, 2017. The most recent transaction is dated Sep 22, 2026.
Across the full history, 12 open-market purchases
and 34 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CAI insider trades is 62.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CAI Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading CAI
Frequently asked
- How many insider trades does FilingIQ track for CAI?
- FilingIQ tracks 235 Form 4 insider transactions for CAI (Caris Life Sciences, Inc.), covering filings from Oct 26, 2017 onwards. 16 of those are dated within the last 90 days.
- Are CAI insiders net buyers or net sellers?
- Across the full Form 4 history for CAI, 12 transactions (5%) were open-market purchases and 34 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CAI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CAI in?
- Caris Life Sciences, Inc. (CAI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.51B.
Methodology & sources
Every CAI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.